Key clinical point: Early FDG-PET imaging may enable safe deescalation of chemotherapy in men with low-volume metastatic seminoma.

Major finding: The deescalated and standard chemotherapy groups had similar 36-month rates of progression-free survival (89.9% and 90%), but the former had a lower cumulative incidence of peripheral neuropathy.

Study details: A single-arm phase 2 trial among 98 patients with good-prognosis metastatic seminoma (SEMITEP trial).

Disclosures: Dr. Loriot disclosed no relevant conflicts of interest. The trial was funded by Institut National du Cancer (Programme Hospitalier de Recherche Clinique). Dr. Albers disclosed honoraria from Sanofi and a consulting or advisory role with MSD, Roche, and Sanofi.